Year: 2024

Aspo PlcPress releaseDecember 23, 2024 at 2:00 pm Aspo SBTi commitment   Aspo Plc has joined the Science Based Targets initiative (SBTi) and committed to set a near-term company-wide science-based emission reduction target, aiming to limit global warming to 1.5°C in line with the Paris Agreement. This commitment builds on the promise made during the Capital Market Day held in May 2024 and reflects Aspo’s ongoing transformation and sustainability journey. The company is now beginning the process of developing and validating its targets in collaboration with SBTi.    Aspo creates value by owning and developing its businesses sustainably and long term. Our companies aim to be market leaders in their sectors and forerunners in sustainability.    “We want to support the transformation towards net zero across the industries we operate in, and...

Schouw & Co. share buy-back programme, week 51 2024 On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 13/12/2024 345,287 558.11 192,707,988    Monday, 16 December 2024 2,000 538.24 1,076,480    Tuesday, 17 December 2024 2,000 530.18 1,060,360    Wednesday, 18 December 2024 2,000 532.19 1,064,380    Thursday,...

DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that a 14th site is now activated and able to enroll subjects in the NEUTRALIZE-AKI pivotal trial. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company’s proprietary therapeutic Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI) in the intensive care unit (ICU) receiving continuous renal replacement therapy (CRRT). “We are pleased to welcome the 14th hospital to our trial, especially as this site has been among the top CRRT programs in the country,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “As of today, 70 of the planned...

Castellum, Inc. Announces Pricing of $3.6 Million Registered Direct OfferingCastellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 9,473,700 shares of common stock in a registered direct offering. The shares of common stock are being sold at an offering price of $0.38 per share – https://castellumus.com/VIENNA, Va., Dec. 23, 2024 (GLOBE NEWSWIRE) — Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it has entered into a securities purchase agreement with several institutional...

TORONTO, Dec. 23, 2024 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”) (TSX VENTURE: PVF) announced today that it has received approval from the TSX Venture Exchange (the “Exchange”) to renew its normal course issuer bids to purchase up to 3,521,732 of its non‐voting equity limited partnership units (the “Equity LP Units”), representing approximately 5% of its currently outstanding Equity LP Units; and to purchase up to 938,226 of its non‐voting Class A preferred limited partnership units, Series 1 (the “Preferred LP Units”), representing approximately 5% of its currently outstanding Preferred LP Units (collectively, the “Bids”). The period of the Bids will be effective from January 3, 2025 to January 2, 2026, or such earlier date that the Partnership completes its purchases. Purchases by the Partnership...

Castellum, Inc. Wins OASIS+ Unrestricted IDIQ ContractCastellum, Inc. (NYSE-American: CTM) (“Castellum”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its subsidiary Specialty Systems, Inc., teaming with Castellum’s other two subsidiaries Corvus Consulting, LLC and Global Technology and Management Resources, Inc., was awarded all four unrestricted domains upon which it submitted proposals – https://castellumus.com/VIENNA, Va., Dec. 23, 2024 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its subsidiary Specialty Systems, Inc., teaming with Castellum’s other two subsidiaries Corvus...

On Track for 50 EH/s in H1 2025 SYDNEY, Dec. 23, 2024 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (together with its subsidiaries, “IREN” or “the Company”) today announced it has reached its year-end target of 31 EH/s installed self-mining capacity, surpassing its original goal of 20 EH/s. Daniel Roberts, Co-Founder and Co-CEO of IREN, commented: “We’re proud to achieve 31 EH/s ahead of schedule, far exceeding the initial year-end target. This year began with just 20MW of operating data centers at Childress, and we successfully expanded that footprint more than 17-fold to 350MW. This remarkable progress is a testament to our 500+ on-site team, whose disciplined approach to procurement, construction, safety and innovation has been instrumental in achieving our ambitious growth targets. Their efforts provide a strong foundation...

In 2025, the consolidated financial results of TKM Grupp AS will be published on the following dates after the closing of market:2024 4th quarter and 12 months interim report January 162024 audited annual report February 202025 1st quarter and 3 months interim report April 92025 2nd quarter and 6 months interim report   July 92025 3rd quarter and 9 months interim report   October 9Raul PuuseppChairman of the BoardPhone: +372 731 5000info@tkmgrupp.ee

11:15 London, 13:15 Helsinki, 23 December 2024 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) NOTICE TO THE EXRTRAORDINARY GENERAL MEETING Notice is given to the shareholders of Afarak Group SE of the Extraordinary General Meeting to be held on 29 January 2025, starting at 10:00 a.m. (Finnish time) at Union Square Auditorium (Floor K1) Unioninkatu 22, 00130 Helsinki, Finland. Registration begins at 9:30 a.m. The shareholders may also exercise their right to vote at the General Meeting by voting in advance. Instructions for advance voting are provided in this General Meeting notice in section C. “Instructions for the participants in the General Meeting”. A. MATTERS ON THE AGENDA OF THE ERTAORDINARY GENERAL MEETING: 1.   Opening of the meeting 2.   Calling the meeting to order 3.   Approval...

On December 20, 2024, AB “Panevėžio statybos trestas” received a notification from UAB Prosperus Group regarding the acquisition of a voting rights of the Company (attached). More information:Tomas Stukas Managing Director Tel.: +370 618 21360AttachmentNotification about voting rights (LT) P